Pancreatic Cancer
Conditions
Keywords
Tarceva, EGFR, erlotinib, OSI-774
Brief summary
The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.
Interventions
DRUGTarceva (erlotinib HCl, OSI-774)
Sponsors
Canadian Cancer Trials Group
OSI Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas;cancer which is unresectable, locally advanced or metastatic. Must have evidence of disease (clinical or radiological). Male or female, 18 years or older. Patients may have received prior radiation treatment for management of local disease providing that disease progression has been documented. All toxicities have resolved, and the last fraction of radiation treatment was completed at least 4 weeks prior to randomization. Patients may not have received prior chemotherapy, other then 5FU (+/- folic acid) or gemcitabine given concurrently with radiation treatment as a 'radiosensitiser.'
Countries
Argentina, Australia, Belgium, Brazil, Canada, Chile, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Romania, Singapore, United Kingdom, United States
Outcome results
None listed